SANDOZ and Mayne Pharma International have announced a partnership granting Sandoz exclusive rights to promote, sell, and distribute Mayne Pharma's Oxycodone IR 5mg and Metaraminol MYX 10mg/1ml Solution for Injection Ampoules in Australia.
Under the agreement, Sandoz will ensure the distribution and sustained access to these medications for Australian patients.
Oxycodone is used for the short-term management of severe pain when other treatments have failed or are unsuitable.
Metaraminol is used for preventing and treating acute hypotensive states during spinal anaesthesia and as an adjunctive treatment of hypotension.
This partnership supports Sandoz's portfolio expansion as an independent entity following its separation from parent company Novartis and aligns with Mayne Pharma's growth strategy for its Australian products.
Clint Holland (pictured left above), General Manager of Sandoz ANZ, expressed pride in the new deal.
"Our partnership with Mayne Pharma reinforces Sandoz's commitment to pioneering access for patients worldwide.
"Following our divestment from Novartis, our purpose remains unchanged," Holland added.
"We aim to become the world's leading generics and biosimilars company, and this partnership is a key component of our growth strategy as an independent entity."
Grant Swart (pictured right above), General Manager of Mayne Pharma, highlighted the alignment of the partnership with their long-term growth strategy.
"Our relationship with Sandoz will establish mutually beneficial relationships with our partners.
"Oxycodone and Metaraminol are well-established in the Australian market, and this agreement will ensure increased availability for patients," Swart commented.
"We look forward to a successful long-term partnership with Sandoz to provide greater access to medicines for patients." JG
The above article was sent to subscribers in Pharmacy Daily's issue from 05 Jun 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Jun 24
